hrp0086rfc14.8 | Growth : Mechanisms | ESPE2016

ACAN Mutations in Short Children Born SGA; Growth Response During GH Treatment with Additional GnRHa, and a Proposed Clinical Scoring System

van der Steen Manouk , Hokken-Koelega Anita C.S.

Background: In children born SGA with persistent short stature, growth hormone (GH) treatment is an approved therapy for increasing adult height (AH). Some SGA children have an advanced bone age (BA) during GH. Heterozygous mutations in the ACAN-gene have been described in children with idiopathic short stature and advanced BA.Objective and hypotheses: To assess growth during GH treatment with additional GnRHa treatment, in children with ACAN-gene mutati...

hrp0092p1-52 | Fat, Metabolism and Obesity | ESPE2019

Effect of Feeding Mode on Longitudinal Body Composition in Early Life

de Fluiter Kirsten S , van Beijsterveldt Inge ALP , Acton Dennis , Hokken-Koelega Anita CS

Background: Excessive gain in fat mass (FM) during the first months of life, known as the critical window for adiposity programming, is associated with an increased risk for adiposity and cardiovascular diseases in later life. Early life nutrition (breastfeeding or formula feeding) might influence body composition (FM and fat free mass (FFM)) development in early life.Aims: To investigate differences in sex-specific long...

hrp0086fc8.5 | Growth: Clinical | ESPE2016

Longitudinal Study on Body Composition, Insulin Sensitivity and β-cell Function in SGA Adults from Stop of Long-term GH Treatment until 5 Years after Stop

van der Steen Manouk , Kerkhof Gerthe F. , Hokken-Koelega Anita C.S.

Background: GH treatment results in a decrease in fat mass (FM) and insulin sensitivity (Si), and an increase in lean body mass (LBM). Only limited data are available on the longitudinal changes after discontinuation of GH treatment in SGA adults, aged 21 years.Objective and hypotheses: To assess longitudinal changes in body composition (BC) and glucose homeostasis after stop of GH treatment in SGA adults.Method: 197 previously GH-...

hrp0086p2-p78 | Adrenal P2 | ESPE2016

Primary Pigmented Nodular Adrenocortical Disease (PPNAD) Justifying a Pediatric Case of ACTH-independent Cushing Syndrome (CS)

Capelo Liana , Vieira Stefania , Apolinario Elisa Cordeiro , Kopacek Cristiane

Background: CS is characterized by excess glucocorticoid excess, either endogenous or exogenous. In children younger than 7 years, the adrenal origin is the most common cause. From this age until adulthood predominates Cushing’s disease (central cause). We can divide CS in ACTH-dependent and independent according to laboratory findings. When ACTH-independent, etiologies are related to benign or malignant diseases of the adrenal or McCune Albright syndrome.<p class="ab...

hrp0094p1-129 | Growth A | ESPE2021

Computer-aided facial analysis as a tool to identify patients with Silver-Russell syndrome and Prader-Willi syndrome

Ciancia Silvia , Goedegebuure Wesley J. , Grootjen Lionne N. , Hokken-Koelega Anita C.S. , Kerkhof Gerthe F. , van der Kaay Danielle C. ,

Introduction: Genetic syndromes often show suggestive facial features that provide clues for the diagnosis. Considering the high number of genetic syndromes and the possible overlap of some features, memorizing facial gestalt is a challenging task for clinicians. DeepGestalt technology, and its app Face2Gene, has a growing impact on the diagnosis and management of genetic diseases by analyzing the features detected in one or more facial images of affected indi...

hrp0097p1-12 | Adrenals and HPA Axis | ESPE2023

Growth and Metabolic Syndrome (MetS) Criteria in children with Classic Congenital Adrenal Hyperplasia (CAH) treated with corticosteroids (CS) versus normal obese children.

Shayma El Sayed , Ashraf Soliman , Noor Hamed , Shayma Ahmed , Fawzia Alyafei , Nada Alaaraj

Introduction: Management of CAH presents unique challenges distinct from other forms of adrenal insufficiency. Higher doses of glucocorticoids are required to suppress adrenal androgen synthesis, which can lead to overtreatment. Steroid-associated adverse events (SAAE) include hypertension, hyperglycemia, and diabetes, overweight and obesity and short stature.Aim: The goal of this study was to assess the occurrence of st...

hrp0092p1-367 | GH and IGFs (2) | ESPE2019

Normal IGF-Bioactivity and Low Free IGF-I in Patients with Prader-Willi Syndrome with High Total Serum IGF-I: Immunoreactive IGF-I Concentration Poorly Reflects IGF Bio-Activity and Bio-Availability.

Elizabeth Melitza , Donze Stephany , Pellikaan Karlijn , van den Berg Sjoerd , van Doorn Jaap , Peeters Robin P. , Hokken-Koelega Anita C.S. , de Graaff Laura C.G.

Introduction: Recombinant Growth Hormone (GH) has changed the lives of many patients with Prader-Willi Syndrome (PWS). GH treatment has beneficial effects on body composition, physical performance, cognition, psychomotor development, respiratory function and quality of life of patients with PWS. Due to the narrow therapeutic range, GH treatment is subject to strict limits. Clinicians measure serum immunoreactive Insulin-like Growth Factor 1 ('total IGF-I&#...

hrp0095p1-266 | Fat, Metabolism and Obesity | ESPE2022

Changes in hypothalamic functional connectivity in the brain following childhood-onset craniopharyngioma

Hinton Elanor , Elsworth Rebecca , Bedford Holly , Hawton Katherine , Narayan Kruthika , Naeem Nimra , Elson Ruth , Taylor-Miller Tashunka , Lithander Fiona , Hamilton-Shield Julian , Crowne Elizabeth

Background: Craniopharyngioma is a non-malignant, embryological brain tumour in the sellar and parasellar region. Hypothalamic damage is common and accompanied by development of obesity in at least 50% of cases. Mechanisms underlying hypothalamic obesity in craniopharyngioma patients however remain unclear and treatment options are invasive and limited. This feasibility study included a novel application of functional neuroimaging, an established method in obe...

hrp0092p1-389 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Eight Years of Growth Hormone Treatment in a Patient with Schaaf-Yang Syndrome

Juriaans Alicia , Hokken-Koelega Anita

Background/Aims: Schaaf-Yang syndrome (SYS) is a rare disorder caused by a truncating mutation in the gene MAGEL2, located in the Prader-Willi critical region on chromosome 15. SYS is characterized as a Prader-Willi-like (PWL) disorder, with neonatal hypotonia, feeding problems in early infancy and intellectual disability, obesity and behavioral problems throughout childhood. In this case report we describe a 15-year-old girl, receiving GH treatment since age ...

hrp0089p1-p152 | GH &amp; IGFs P1 | ESPE2018

Microalbuminuria and Glomerular Filtration Rate in SGA Born Young Adults

Goedegebuure Wesley , Hokken-Koelega Anita

Background: Following Barker’s hypothesis on fetal growth retardation, low birth weight and being born small for gestational age (SGA) might be linked to fewer glomeruli which influences adult disease. Growth hormone (GH) treatment leads to a greater kidney length and total kidney volume, as well as a higher glomerular filtration rate (GFR). Microalbuminuria, defined as more than 20 mg/l albumin in random urine sample, is a marker for renal diseases and is a risk factor f...